Phase 3 Readout~month

Phase 3 Topline: Efficacy and Safety of Gene Therapy rAAV-RPE65 (LX101) in Biallelic RPE65 Mutation-associated Inheri

Indication
Inherited Retinal Dystrophy Associated With RPE65 Mutations

Other upcoming events for SABS

Phase 2 StartPhase 2 Start: An Open, Multicenter Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics
Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of
Patent ExpiryPatent/Exclusivity Expiry: FORZINITY

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Efficacy and Safety of Gene Therapy rAAV-RPE65 (LX101) in Biallelic RPE65 Mutation-associated Inheri — SABS Phase 3 Readout | BioSniper